Evidence map›Paper›PMID 34269808›Full record

ArticleJAMA network open2021

Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act.

Juan F Javier-DesLoges, Julia Yuan, Shady Soliman, Kevin Hakimi, Margaret F Meagher, Fady Ghali, Walter Hsiang, Devin N Patel, Simon P Kim, James D Murphy and 2 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Juan F Javier-DesLogesDepartment of Urology, University of California, San Diego, School of Medicine, La Jolla.
Julia YuanUniversity of California, San Diego, School of Medicine, La Jolla.
Shady SolimanUniversity of California, San Diego, School of Medicine, La Jolla.
Kevin HakimiUniversity of California, San Diego, School of Medicine, La Jolla.
Margaret F MeagherUniversity of California, San Diego, School of Medicine, La Jolla.
Fady GhaliDepartment of Urology, University of California, San Diego, School of Medicine, La Jolla.
Walter HsiangDepartment of Urology, Yale University School of Medicine, New Haven, Connecticut.
Devin N PatelDepartment of Urology, University of California, San Diego, School of Medicine, La Jolla.
Simon P KimDepartment of Urology, University of Colorado Anschutz School of Medicine, Denver.
James D MurphyDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, School of Medicine, La Jolla.
J Kellogg ParsonsDepartment of Urology, University of California, San Diego, School of Medicine, La Jolla.
Ithaar H DerweeshDepartment of Urology, University of California, San Diego, School of Medicine, La Jolla.
University of California, San Diego · USUniversity of Colorado Anschutz Medical Campus · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: The association of the Patient Protection and Affordable Care Act (ACA) with insurance status and cancer stage at diagnosis among patients with renal cell carcinoma (RCC) is unknown. Objective: To test the hypothesis that the ACA may be associated with increased access to care through expansion of insurance, which may vary based on income. Design, Setting, and Participants: This retrospective cohort analysis included patients diagnosed with RCC from January 1, 2010, to December 31, 2016, in the National Cancer Database. Data were analyzed from July 1 to December 31, 2020. The periods from 2010 to 2013 and from 2014 to 2016 were defined as pre- and post-ACA implementation, respectively. Patients were categorized as living in a Medicaid expansion state or not. Exposures: Implementation of the ACA. Main Outcomes and Measures: The absolute percentage change (APC) of insurance coverage was calculated before and after ACA implementation in expansion and nonexpansion states. Secondary outcomes included change in stage at diagnosis, difference in the rate of insurance change, and change in localized disease between expansion and nonexpansion states. Adjusted difference-in-difference modeling was performed. Results: The cohort included 78 099 patients (64.7% male and 35.3% female; mean [SD] age, 54.66 [6.46] years), of whom 21.2% had low, 46.2% had middle, and 32.6% had high incomes. After ACA implementation, expansion states had a lower proportion of uninsured patients (adjusted difference-in-difference, -1.14% [95% CI, -1.98% to -1.41%]; P = .005). This occurred to the greatest degree among low-income patients through the acquisition of Medicaid (APC, 11.0% [95% CI, 8.6%-13.3%]; P < .001). Implementation of the ACA was also associated with an increase in detection of stage I and II disease (APC, 4.0% [95% CI, 1.6%-6.3%]; P = .001) among low-income patients in expansion states. Conclusions and Relevance: Among patients with RCC, ACA implementation was associated with an increase in insurance coverage status in both expansion and nonexpansion states for all income groups, but to a greater degree in expansion states. The proportion of patients with localized disease increased among low-income patients in both states. These data suggest that ACA implementation is associated with earlier RCC detection among lower-income patients.

Indexed as

AdultCarcinoma, Renal CellCohort StudiesCorrelation of DataFemaleHumansInsurance CoverageMaleMiddle AgedNeoplasm StagingPatient Protection and Affordable Care ActPovertyRetrospective Studies

Identifiers

PMID34269808
PMCPMC8285737
OpenAlexW3181666936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.